Law of Minimum Dose

Michael Frass et al. (2026) · Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

This three-arm, double-blind, placebo-controlled trial (98 randomized patients plus 52 observed controls) examined whether add-on homeopathy — an individualized complementary treatment using highly diluted plant-, mineral-, or animal-derived preparations chosen for each patient's overall symptom picture — could improve quality of life and survival in people with advanced non-small cell lung cancer (NSCLC, the most common form of lung cancer) already receiving standard chemotherapy. An earlier report of this exact same trial dataset was published in The Oncologist in 2020 and was retracted by that journal in November 2025 after two corrections, a decision most of the trial's own co-authors disagreed with; this article is an independently re-analyzed, more conservative account of the same underlying data. Ninety-eight adults (mean age 63, most with stage IV NSCLC) at four Austrian hospitals were randomly assigned, double-blind, to individualized homeopathic remedies or an identical-looking placebo alongside their usual chemotherapy, while a further 52 patients who declined randomization were tracked as an untreated comparison group. Quality of life was measured with the EORTC QLQ-C30 cancer questionnaire, the SF-36 health survey, and a visual-analogue well-being scale at the start of treatment and again at 9 and 18 weeks, while survival was followed for up to two years. Patients receiving homeopathy reported markedly better global health status than the placebo group at both 9 and 18 weeks (p<0.001, a difference well above the 10-point size doctors consider clinically meaningful), and nearly every functioning and symptom score — physical, emotional, and social functioning, fatigue, pain, and appetite among them — favored homeopathy by 18 weeks; results from the SF-36 health survey and the well-being scale pointed the same direction. Survival differed too: median survival was 435 days with homeopathy versus 257 days with placebo (p=0.010) and 228 days in the untreated comparison group, translating to 2-year survival rates of 45.1%, 23.4%, and 13.5% respectively (homeopathy vs. placebo p=0.020; homeopathy vs. control p<0.001). No side effects were attributed to either the homeopathic remedy or the placebo, and every death in the trial was confirmed to be a direct result of the cancer itself rather than a treatment complication. The authors are careful to note that their design cannot tell whether the benefit came from the remedy itself or from the long, attentive homeopathic consultation both randomized groups received; that the untreated comparison group was not randomized and may differ from the treated groups in ways beyond homeopathy; and that the trial ran before modern immunotherapy became standard NSCLC care. Combined with the dataset's retraction history, these findings should be read as encouraging but preliminary, awaiting independent replication by researchers not previously involved in homeopathy research before they influence clinical decisions.